{"entity":{"id":"nct06598787","kind":"trial","name":"A Study of BL-B01D1 in Patients With Recurrent Glioblastoma","aka":[],"tldr":"A phase 2 trial of BL-B01D1 for Injection in glioma & glioblastoma, run by Sichuan Baili Pharmaceutical Co., Ltd., now recruiting.","summary":"A Study of BL-B01D1 in Patients With Recurrent Glioblastoma is a phase 2 interventional study registered as NCT06598787 by Sichuan Baili Pharmaceutical Co., Ltd., with 20 participants planned, started 2024-10-17 and due to reach its primary completion in 2026-10. Interventions recorded: BL-B01D1 for Injection.","status":"recruiting","asOf":"2026-09-16","links":[{"label":"ClinicalTrials.gov NCT06598787","url":"https://clinicaltrials.gov/study/NCT06598787"}],"tags":["pipeline","ctgov-ingest"],"related":[],"cancers":["glioblastoma"],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":["systimmune"],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"notes":[],"nct":"NCT06598787","phase":"2","setting":"A Phase II Clinical Study to Evaluate the Efficacy and Safety of BL-B01D1 for Injection in Patients With Recurrent Glioblastoma","sponsor":"Sichuan Baili Pharmaceutical Co., Ltd.","enrolled":20,"outcomes":[]},"route":"/trials/nct06598787/","neighbours":{"cancer":[{"id":"glioblastoma","kind":"cancer","name":"Glioma & glioblastoma","route":"/cancers/glioblastoma/"}],"company":[{"id":"systimmune","kind":"company","name":"SystImmune / Sichuan Biokin","route":"/companies/systimmune/"}]}}